Article
AI-Driven Identification and Validation of RXFP1 as a CML Biomarker Using Gene Expression and Integrated GUI Tools
2025-06-09
Abstract excerpt
Chronic myeloid leukemia (CML) is a hematologic malignancy primarily driven by the BCR-ABL1 fusion gene. While tyrosine kinase inhibitors (TKIs), such as imatinib, have transformed CML management, many patients still experience adverse side effects and therapy resistance. This study investigated the potential of RXFP1 (relaxin family peptide receptor 1) as a diagnostic biomarker for CML, leveraging bioinformatics,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 00553758-e3c6-5147-b889-a2aebdd98391
- DOI
- 10.1101/2025.06.06.658261
